Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | PHASE1 | RECRUITING | 90 | — | — | Sep 12, 2025 | May 31, 2028 | Oct 2, 2025 | 1 | China |
Incidence of adverse events during the study, evaluated per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) criteria
Dose-limiting toxicity after CD70 CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Intrapleural infusion of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Intraperitoneal infusion of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Name | Type | Description |
|---|---|---|
| CD70-targeted CAR-T cells | BIOLOGICAL | Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion. |
Inclusion Criteria: 1. Age ≥18 years, regardless of gender; 2. Histologically or cytologically confirmed advanced/metastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score); 3. Failed or intolerant to standard second-line treatments (at least on...